Amolyt Pharma have announced positive results from the second patient cohort of their Phase 2a Clinical Trial investigating AZP-3601 as a potential treatment for hypoparathyroidism .
Amolyt say “We’re excited to be one step closer to helping patients in need.”
See their patient page here